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Purpose: To compare in vitro properties of 4 drug-eluting embolic agents loaded with doxorubicin.
Materials and Methods: DC Bead (100–300 mm), LifePearl (200 mm), HepaSphere (30–60 mm), and Tandem (100 mm)
microspheres were loaded with 40 mg/20 mL of doxorubicin per milliliter of microspheres. Loading, elution, diameter changes
after loading, changes in the amount of doxorubicin loaded over 2 weeks in storage, and time in suspension were evaluated.
Results: All microspheres loaded4 99% doxorubicin within 1 hour. In vitro elution reached a plateau by 6 hours, with 30% 
5, 21%  2, 8%  3, and 6%  0 of the loaded doxorubicin eluted for LifePearl, DC Bead, HepaSphere, and Tandem
microspheres, respectively, with at least 1 statistically signiﬁcant difference between at least 2 of the products in doxorubicin
eluted at every time point. The times to elute 75% of the total released doxorubicin were 197, 139, 110, and 77 min for DC Bead,
LifePearl, HepaSphere, and Tandem microspheres, respectively. The average diameters of LifePearl, DC Bead, and Tandem
microspheres were reduced after loading by 24%, 20%, and 9%, respectively. After suspension in contrast medium, no changes
were observed in doxorubicin loading over 2 wk. After loading, times in suspension were 8.4 min  0.2, 6.0 min  0.1, 3.1 min
 0.2, and 2.9 min  0.3 for Tandem, LifePearl, DC Bead, and HepaSphere microspheres, respectively.
Conclusions: Although drug-eluting embolic agents universally loaded doxorubicin within 1 hour, the elution amounts, rates of
release, diameter shrinkage, and times in suspension varied by product.
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vir.2016.05.015drug-eluting embolic agents are commercially available
for use with doxorubicin, including DC Bead (BTG,
Farnham, United Kingdom), HepaSphere (Merit Medi-
cal, South Jordan, Utah), LifePearl (Terumo European
Interventional Systems, Leuven, Belgium), and Tandem
(Boston Scientiﬁc, Marlborough, Massachusetts) mi-
crospheres. DC Bead microspheres consist of a poly-
vinyl alcohol hydrogel modiﬁed with sulfonate groups
(2). HepaSphere microspheres consist of a poly(vinyl
alcohol-co-sodium acrylate) hydrogel (3). LifePearl
microspheres consist of a hydrogel network of poly
(ethylene glycol) and 3-sulfopropyl acrylate. Tandem
microspheres consist of a hydrogel core made of sodium
poly(methacrylate) and an outer biocompatible shell of
poly(bis[triﬂuoroethoxy]phosphazene) (4). For all four
types of microspheres, the drug loading mechanism is the
ionic interaction of the cationic doxorubicin with the
anionic functional groups of the microspheres.
Despite the clinical use of several types of doxorubicin-
loaded microspheres, a systematic analysis of the similarities
de Baere et al ’ JVIR1426 ’ In Vitro Evaluation of Four Types of Doxorubicin-Eluting Microspheresand differences of the commercially available products is
lacking. The in vitro characteristics of DC Bead and
HepaSphere microspheres loaded with doxorubicin have
been reported (2,5); however, the characteristics of Life-
Pearl and Tandem microspheres loaded with doxorubi-
cin have not been reported to our awareness. As such,
the purpose of the present study was to compare in vitro
properties of DC Bead, HepaSphere, LifePearl, and
Tandem microspheres loaded with doxorubicin.MATERIALS AND METHODS
Materials
Microspheres evaluated in this study included DC Bead
(100–300 mm), HepaSphere (30–60 mm dry and 120–240
mm expanded), LifePearl (200 mm), and Tandem (100 mm)
microspheres. Generic doxorubicin hydrochloride (Pﬁzer,
New York, New York) at a concentration of 2 mg/mL
and nonionic Omnipaque (GE Healthcare, Princeton,
New Jersey) 300 mgI/mL were used in this study.
Doxorubicin Loading, Elution, and Loading
Stability
Each package of microspheres, containing 2 mL of
microspheres, was split into two equal samples to form
1-mL aliquots. Doxorubicin loading of ﬁve aliquots of
each product was then evaluated in accordance with the
manufacturers’ instructions. The excess supernatant was
removed, and 20 mL of doxorubicin (40 mg) solution
was added. The microspheres were agitated on a rocker
during the incubation. At 0.25, 0.5, 1, 2, 3, 4, 5, and 24
hours of incubation, 50 mL of the solution was removed
and diluted with 1.0 mL of water, and the concentration
of doxorubicin was quantiﬁed by using a validated high-
performance liquid chromatography (HPLC) method.
Brieﬂy, doxorubicin concentration was quantiﬁed by
using an Agilent 1260 Inﬁnity HPLC system with a
Phenomenex Gemini-NX 3-mm C18 column (4.6 mm 
50 mm) from 5 to 400 ppm. The mobile phase was 73:27
15 mM NH4OH/(NH4)3PO4 (pH 10):acetonitrile at a
rate of 1 mL/min. The injection volume was 10 mL, and
the wavelength was 234 nm. Mass and percentage
loading were calculated from the concentration data.
The diameters of unloaded and doxorubicin-loaded
microspheres were measured by using an AxioZoom
V.16 motorized stereo zoom microscope with a Plan
NEOFLUAR Z 1/0.25 free working distance 56 mm
objective and an AxioCam high-resolution cooled cam-
era (Zeiss, Thornwood, New York). Diameter measure-
ments were calculated by using AxioVision SE64
measurement software (Zeiss). For each measurement
group, the diameter of at least 200 mm was determined.
For determination of elution, doxorubicin-loaded micro-
spheres were placed in one of seven ﬂow cells of a CE
7smart USP 4 system (Sotax, Westborough, Massachusetts).
Five replicates per microsphere group were evaluated.The Sotax elution system was prepared with a 500-mL
sink of 0.9% saline solution per channel at a temperature
of 371C and a ﬂow rate of 8.0 mL/min. Samples, 1 mL
per time point, were taken at 0.33, 0.67, 1, 2, 3, 4, 5, 6,
and 24 hours after the beginning of the elution. Doxoru-
bicin concentration was determined by using the validated
HPLC method described earlier. Mass and percentage
elution were calculated from the concentration data.
For determination of stability of the loading over time
in storage, doxorubicin-loaded microspheres were placed
in 65:35 (volume/volume) contrast agent:water for injec-
tion solution or 100% contrast agent. Five replicates per
microsphere group were evaluated per aqueous solution.
After loading, microspheres were placed in 10 mL of the
solution and stored at 41C. At periodic time points from
1 hour to 10 days, samples were collected and analyzed
by using a validated HPLC method with a range from 5
to 400 ppm to quantify the doxorubicin in the ﬂuid.
Brieﬂy, with the use of the same equipment and column
described earlier, a gradient method with the same
mobile phases was used. The injection volume was 10
mL. The mobile phase ﬂow rate was 1 mL/min with
15%–33% acetonitrile from 0 to 2.5 minutes and 33%
acetonitrile from 2.5 to 2.6 minutes. Mass and percent-
age elution were calculated from the concentration data.
Time in Suspension
Time in suspension was evaluated for doxorubicin-
loaded microspheres in a manner previously described
(6). Six replicates per microsphere group were evaluated.
After loading, the supernatant was expressed from the
microspheres and replaced with 8 mL of 50:50 Omni-
paque 300:water for injection (volume/volume) solution
in a 10-mL syringe. The microspheres and contrast
agent:water solution was mixed by 15 passes of syringe-
to-syringe mixing. At the end of the mixing, all the
contents were placed in one syringe, and that syringe was
immediately placed vertically on a countertop. The time
taken for the microspheres to vacate one third of the
syringe was taken as the time in suspension.
Statistical Analysis
Statistical analyses were performed by using Minitab 17
(Minitab, State College, Pennsylvania). Differences in
continuous data were assessed by using a one-way Welch
analysis of variance. If the analysis of variance indicated
a signiﬁcant difference, a two-tailed t test was performed
to identify the speciﬁc differences. Statistical signiﬁcance
was accepted at α r 0.05.RESULTS
Doxorubicin Loading, Elution, and Loading
Stability
All four microsphere types quickly and repeatedly
loaded doxorubicin (Fig 1). HepaSphere microspheres
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microspheres were rehydrated by the doxorubicin
solution. Loading of more than 99% of doxorubicin in
the solution was achieved within 1 hour for all
microspheres. The loading of HepaSphere microspheres
was signiﬁcantly greater than that of DC Bead
microspheres at 15 minutes (P ¼ .001), 30 minutes
(P ¼ .001), 1 hour (P ¼ .01), and 3 hours (P ¼ .01).
The loading of LifePearl microspheres was signiﬁcantly
greater than that of DC Bead microspheres at 15
minutes (P ¼ .04) and 30 minutes (P ¼ .01). The
loading of HepaSphere microspheres was signiﬁcantly
greater than that of Tandem microspheres at 1 hour
(P ¼ .001), 3 hours (P ¼ .001), 4 hours (P ¼ .0001), and
5 hours (P ¼ .001). The loading of Tandem micro-
spheres was signiﬁcantly greater than that of DC Bead
microspheres at 30 minutes (P ¼ .001), 1 hour (P ¼ .01),
and 24 hours (P ¼ .001). At 24 hours, the loading of
Tandem microspheres was signiﬁcantly greater than that
of LifePearl microspheres (P ¼ .001).
DC Bead, LifePearl, and Tandem microspheres were
separate and spherical before and after loading with
doxorubicin, whereas HepaSphere microspheres were
not uniformly spherical after hydration and loading with
doxorubicin (Fig 2). LifePearl and Tandem microspheres
had more uniformity in diameter compared with DC
Bead when unloaded and doxorubicin-loaded (Fig 3,
Table 1).
The diameters of LifePearl, DC Bead, and Tandem
microspheres were reduced after loading by 24%, 20%,
and 9%, respectively (Table 1). Because the HepaSphere
microspheres were reconstituted from a dry state by the
doxorubicin solution, changes in diameter could not be
determined. Although the Tandem microspheres did not
change diameter appreciably after loading with doxo-
rubicin, approximately 3% of the doxorubicin-loaded
microspheres were smaller than 50 mm.Figure 1. Doxorubicin loading of DC Bead, HepaSphere, LifePearl, an
range to illustrate the differences in loading.For all types of microspheres, elution reached a
plateau by 6 hours, without further elution at 24 hours.
LifePearl, DC Bead, HepaSphere, and Tandem micro-
spheres eluted 30%  5, 21%  2, 8%  3, and 6%  0
of the loaded doxorubicin, respectively. The times to
elute 75% of the total released doxorubicin were 197,
139, 110, and 77 minutes for DC Bead, LifePearl,
HepaSphere, and Tandem microspheres, respectively
(Fig 4). At 20 minutes, the differences in doxorubicin
elution were statistically signiﬁcant between LifePearl
microspheres and DC Bead (P ¼ .01), Tandem (P ¼
.02), and HepaSphere (P ¼ .2) microspheres. At 40
minutes, 1 hour, 2 hours, 3 hours, 5 hours, 6 hours, and
24 hours, the differences were signiﬁcant for DC Bead
microspheres compared with LifePearl (P ¼ .01–.03),
Tandem (P ¼ .001–.01), and HepaSphere (P ¼
.001–.004) microspheres, as well as for LifePearl
microspheres compared with Tandem (P ¼ .001–.01)
and HepaSphere (P ¼ .001–.01) microspheres. At 4
hours, the differences were signiﬁcant for DC Bead and
LifePearl microspheres compared with HepaSphere (P ¼
.001–.01) and Tandem (P ¼ .01–.001) microspheres.
Mixing doxorubicin-loaded microspheres with 100%
contrast agent or 65%:35% contrast agent:water for
injection did not result in signiﬁcant elution of doxor-
ubicin (Fig 5). Approximately 0.5 mg (1%) was
immediately eluted from the microspheres, and no
further doxorubicin release was observed over a period
of 10 days for all four types of microspheres.
Time in Suspension
The time in suspension, ie, the amount of time for the
microspheres to vacate one third of the volume of a 10-
mL syringe, was greatest for Tandem, followed by
LifePearl, and further followed by DC Bead and Hepa-
Sphere microspheres. Differences in the times in sus-
pension were not signiﬁcant between DC Bead andd Tandem microspheres: (a) entire duration and (b) reduced time
Figure 2. Photomicrographs of doxorubicin-loaded LifePearl (a), DC Bead (b), Tandem (c), and HepaSphere (d) microspheres. Inset
images in the lower left corners are photomicrographs of unloaded microspheres. (Scale bars: 200 mm.)
Figure 3. Diameter distribution histograms of doxorubicin-loaded DC Bead, HepaSphere, LifePearl, and Tandem microspheres.
de Baere et al ’ JVIR1428 ’ In Vitro Evaluation of Four Types of Doxorubicin-Eluting MicrospheresHepaSphere microspheres (P ¼ .21). For each product,
the time in suspension did not differ for immediate
suspension upon mixing with contrast agent or for as
long as 30 minutes after mixing (Table 2).In the present study, the in vitro performance of four
types of microspheres loaded with doxorubicin wasDISCUSSION
evaluated. Although there are many similarities among
Volume 27 ’ Number 9 ’ September ’ 2016 1429the four types, each type has a unique chemistry that
imparts unique properties to the microspheres. This
study demonstrates the similarities and differences
among the four microsphere types.
All four types of microspheres loaded doxorubicin in
less than 1 hour. The loading of doxorubicin in DC Bead
and HepaSphere microspheres has been previously
evaluated (2). Loading was slower in the previous
report than observed in the present study, with almost
complete loading between 1 and 1.5 hours (2). This
difference may be a result of the diameter of micro-
spheres that were evaluated in the two studies. In the
present study, relatively small microspheres (100–300 mm
in diameter) were used, whereas previous studies
evaluated larger microspheres (500–700-mm DC Bead
and 400–600-mm HepaSphere microspheres) were eva-
luated (2). The effect of microsphere size on doxorubicin
loading may be a result of the increased surface area of
the smaller microspheres, resulting in greater area ex-
posed to the doxorubicin solution. Although the
doxorubicin loading of LifePearl and Tandem micro-
spheres has not been previously investigated to our
knowledge, the loading of idarubicin, a chemical ana-
logue of doxorubicin, into DC Bead and TandemTable 1 . Diameters of Unloaded and Doxorubicin-Loaded
Microspheres
Microsphere Type
Diameter (lm)
Unloaded Doxorubicin-Loaded
LifePearl 199  24 151  18
DC Bead 173  53 138  46
Tandem 98  15 89  15
HepaSphere NA 165  28
Note–Values presented as means  standard deviation.
NA ¼ not applicable.
Figure 4. Doxorubicin elution in a dissolution apparatus of DC Bea
duration and (b) reduced time range to illustrate the differences in elumicrospheres has been evaluated (4). In that study (4),
idarubicin loading was 4 99% complete within 10
minutes, a result of reduced quantity of drug to be
loaded (5–15 mg idarubicin compared with 40 mg of
doxorubicin in the present study).
Visually, in the present study, DC Bead, LifePearl,
and Tandem microspheres were separate, spherical, and
uniformly colored by doxorubicin. HepaSphere micro-
spheres were clumped, somewhat spherical, and not
uniformly colored by doxorubicin. This study conﬁrms
the visual appearance of DC Bead and HepaSphere
microspheres as previously reported (2). The appearance
of LifePearl and Tandem microspheres after loading
with doxorubicin has not been previously reported to
our knowledge.
Although the reduction in average diameter of the
microspheres after loading with doxorubicin is a well-
known effect of water displacement from the micro-
sphere as a result of the ionic loading process (2,4), the
effects on the entire distribution of microsphere diame-
ters has not been previously reported to our knowledge.
Although the reduction in the average diameter is
important, another important piece of information is
the diameter of the smallest microspheres, in view of the
concern about shunting from the hepatic artery (where
microspheres are intended to be injected) toward the
hepatic or portal veins, which can result in major
complications such as liver or pulmonary infarction.
A previous report (7) described three fatal pulmonary
embolisms as a result of 40–120-mm microspheres pass-
ing through hepatic shunts. The same center has not seen
this complication when using 100–200-mm microspheres.
In the present study, only Tandem microspheres had
individual microspheres smaller than 50 mm in diameter.
The present study conﬁrms previous reports that
doxorubicin is eluted in differing amounts depending
on the microsphere. The 21% release for DC Bead andd, HepaSphere, LifePearl, and Tandem microspheres: (a) entire
tion.
Figure 5. Stability of doxorubicin loading of DC Bead, HepaSphere, LifePearl, and Tandem microspheres in 65:35 contrast agent:water
for injection (a) and 100% contrast agent (b) over a period of 10 days at 4 1C.
Table 2 . Time in Suspension for the 4 Types of Microspheres
Microsphere Type Time in Suspension (s)
LifePearl 357  7
DC Bead 185  11
Tandem 504  12
HepaSphere 172  20
Note–Values presented as means  standard deviation.
de Baere et al ’ JVIR1430 ’ In Vitro Evaluation of Four Types of Doxorubicin-Eluting Microspheres8% release for HepaSphere microspheres is consistent
with previous reports (2). For all four microsphere
types, doxorubicin is loaded via ionizable functional
groups on the hydrogel material, a carboxylate for
HepaSphere (3) and Tandem microspheres (8) and a
sulfonate for DC Bead (2) and LifePearl microspheres.
The negatively charged carboxylate or sulfonate inter-
acts with the positively charged doxorubicin during
loading. The interaction is disrupted during elution as
the sodium ion replaces doxorubicin as a result of the
increased ionic strength of the phosphate-buffered
saline solution. Because carboxylic acids have higher
pKa values than sulfonic acids, the use of carboxylic
acids require a higher pH for the acid to be deprotonated
and able to participate in ionic interactions. If ionic
interaction is the major factor governing doxorubicin
loading and elution, the different acidities of carboxylic
acids and sulfonic acids would not cause signiﬁcant
differences in doxorubicin loading and elution because
the experiments were performed at a pH at which
carboxylic and sulfonic acids are fully deprotonated.
The present study shows that ionic interaction is the
major interaction affecting doxorubicin loading, as
carboxylic and sulfonic acid–based microspheres loaded
equally.However, signiﬁcant differences in doxorubicin elu-
tion were observed from microspheres containing car-
boxylic and sulfonic acids, indicating that other
mechanisms besides ionic interaction are involved in
doxorubicin elution. Structurally, doxorubicin contains
ﬁve hydroxyl groups, which could potentially participate
in hydrogen bonding to microsphere materials. Addi-
tionally, doxorubicin is known to aggregate and form
dimers, trimers, and higher-order aggregates (9). These
aggregates possess multiples of positive charges and
therefore bond more strongly with the anionic mate-
rials and require greater ionic strength to elute relative to
single molecules of doxorubicin. As the four types of
microspheres evaluated in the present study are com-
posed of different materials, the degree of hydrogen
bonding and doxorubicin aggregation inside the micro-
spheres may vary signiﬁcantly, leading to differing elu-
tion rates of doxorubicin.
The present study conﬁrms a previous report of
doxorubicin stability with DC Bead microspheres over
a period of 14 days (10) and further demonstrates the
stability of HepaSphere, LifePearl, and Tandem micro-
spheres loaded with doxorubicin, which has not been
previously reported to our knowledge. The decrease in
the amount of doxorubicin in the solution over time
may be a result of degradation of doxorubicin. Pre-
vious reports have shown that the stability of doxo-
rubicin is greatest at low pH and that some degradation
and adsorption of doxorubicin occurs at neutral pH
(11,12).
Time in suspension is an important characteristic of
drug-eluting embolic agents because it impacts the
ease of use of the product. Microspheres with longer
times in suspension will allow for a smoother emboliza-
tion procedure without the need for an interruption to
resuspend the microspheres. Despite its impact on ease
Volume 27 ’ Number 9 ’ September ’ 2016 1431of use, time in suspension appears to be largely unstu-
died in doxorubicin-loaded microspheres. In the present
study, Tandem microspheres remained in suspension the
longest. This may be partially explained by Tandem
microspheres having the smallest microsphere diameters
of the four groups in the study. Smaller microspheres are
known to go into suspension quicker and remain in
suspension longer than larger microspheres as a result of
their increased buoyancy.
There are limitations to the present study. First, the
microsphere types did not have identical diameter
ranges. For example, the LifePearl microspheres ranged
from 150 to 250 mm in diameter, whereas the Tandem
microspheres ranged from 75 to 125 mm in diameter. The
effect of the diameter on the performance of the micro-
sphere is unknown and may preclude direct comparison.
However, previous reports have shown that loading and
elution of doxorubicin is more rapid with microspheres
with smaller diameters (5).
Second, doxorubicin elution was measured by using
a Sotax dissolution apparatus. This equipment is the
standard for elution studies, as several previous studies
have used it to study elution from drug-eluting embolic
agents (2,4). Although the phosphate-buffered saline
solution used in the Sotax equipment accurately reﬂects
the osmolarity and pH of blood, the in vivo milieu is far
more complex than pH and osmolarity. The correlation
between in vitro elution in phosphate-buffered saline
solution and in vivo elution in the liver vasculature is
unknown; however, a previous study (13) investigated
the differences between in vitro and in vivo elution of
doxorubicin.
In conclusion, the present study identiﬁed the similari-
ties and differences of four commercially available
microspheres loaded with doxorubicin. For all four
microsphere types, doxorubicin loading was rapid and
nearly complete. However, in vitro doxorubicin elution
was slow and incomplete, with differences in total elu-
tion among the microsphere types. Currently, it is un-
known whether these differences have an impact in vivo.ACKNOWLEDGMENT
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